We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .

Essential enable/disable

These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name	Webedition CMS
Purpose	This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.

External media enable/disable

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name	YouTube
Purpose	Show YouTube content
Name	Twitter
Purpose	activate Twitter Feeds

Research

Sebastian Kruse, PhD

PhD Student, then Postdoctoral Scientist

Orcid ID: 0000-0002-4028-1391

Scientific CV

Jan 2019 - Dec 2019
Postdoctoral scientist, Immunotherapy and Immunoprevention, DKFZ, Heidelberg

2015 - 2019
PhD student, Junior Research Group Immunotherapy and Immunoprevention, DKFZ, Heidelberg

2012 - 2015
MSc Biological Sciences, Focus Disease Biology, University of Konstanz

Jan 2014 - Jun 2014
ERASMUS exchange term, “Tumor Immunology”, La Sapienza University, Rome, Italy

Sep 2013 - Nov 2013
Research Internship, “Tumor Immunology & Cancer Stem Cells”, University Hospital Bern, Bern, Switzerland

2009 - 2012
BSc Biological Sciences, University of Konstanz

Research Project

Development of an optimal vaccination approach for minimal epitope-based therapeutic vaccines against HPV-induced malignancies in a humanized mouse model

In this project, we used HPV16 epitopes that were confirmed by mass spectrometry to be presented to the immune system on human cancer cells. These epitopes were used in several vaccine formulations to induce high numbers of specific cytotoxic T cells in a mouse model that was humanized for major histocompatibility complex (MHC) class I and class II molecules. In addition, a suitable tumor model for these mice was developed in this project. The final goal was to compare the tested vaccine formulations for mediating anti-tumor effects. Testing human epitopes in a humanized model system is expected to increase the translatability of the findings to the clinical setting.

Resulting Publications

Therapeutic vaccination using minimal HPV16 epitopes in a novel MHC-humanized murine HPV tumor model.
Kruse S, Büchler M, Uhl P, Sauter M, Scherer P, Lan TCT, Zottnick S, Klevenz A, Yang R, Rösl F, Mier W, Riemer AB.
OncoImmunology 2018, 8(1): e1524694.